Amgen's Imdelltra Sales Jump 115% as Imfinzi Combo Hits Goals

Amgen reported that sales of its small-cell lung cancer drug Imdelltra rose 115% and that a 563-patient late-stage trial combining Imdelltra with AstraZeneca's Imfinzi met major goals, improving survival and response measures.

Amgen Inc. (AMGN) delivered the two things a drugmaker most wants on the same day: a commercial number moving fast in the right direction, and late-stage clinical data that widens where the drug can be used. Sales of Imdelltra, the company's treatment for small-cell lung cancer, surged 115%, while a 563-patient Phase 3 trial testing Imdelltra alongside AstraZeneca's Imfinzi met its major goals, improving both survival and response measures.

The market's reaction was muted, and the reason had little to do with oncology. Amgen changed hands at 390.64 as of 18:51 GMT on Wednesday, 9 September 2026, down 0.64% from a prior close of 393.17, with an intraday band of 389.28 to 395.55. That put the stock in line with a soft tape rather than against it: the SPDR S&P 500 ETF (NYSEARCA: SPY) was off 0.37% at $763.13, the Invesco QQQ Trust (NASDAQ: QQQ) down 0.24% at $716.61, and the SPDR Dow Jones Industrial Average ETF (NYSEARCA: DIA) lower by 0.64% at $524.63. On a day when the broad market drifted, a positive readout did not pull the shares out of the downdraft.

What a 115% sales increase says about the launch curve

Growth rates that high are the signature of a young product still building its prescriber base rather than a mature franchise defending share. Imdelltra addresses small-cell lung cancer, historically one of the least tractable thoracic tumours, where patients who progress after platinum-based chemotherapy have had few durable options. A doubling-plus in sales suggests the drug is moving beyond early adopters at academic centres and into community oncology practice, which is where volume in US cancer care actually lives.

What the headline figure does not settle is the base it grew from. A 115% increase on a small denominator is a different business proposition from the same percentage on an established one, and Amgen has not, in the material at hand, attached a dollar amount to it. Investors sizing the franchise should therefore treat the percentage as a directional signal about uptake speed, not as a proxy for scale. The more informative question over the next few quarters is whether the rate of increase holds as the addressable pool of previously treated patients is worked through.

The Imfinzi combination is the bigger strategic prize

The trial result matters more than the sales line, because it points at a larger patient population. Imdelltra's commercial footprint to date has been in patients whose disease has already progressed. Pairing it with Imfinzi, AstraZeneca's PD-L1 checkpoint inhibitor, is an attempt to move the drug earlier in the treatment sequence, where immunotherapy maintenance has become standard practice in extensive-stage small-cell disease. Earlier lines mean more patients and longer duration of therapy per patient — the two levers that turn a specialty launch into a major franchise.

The design detail worth noting is the endpoint mix. Amgen reported improvements in both survival and response measures across the 563-patient study, as first detailed by GuruFocus. Response rate tells regulators and physicians that tumours shrink; survival tells them that the shrinkage translates into time. Trials in small-cell lung cancer have repeatedly produced the former without the latter, which is why a combination clearing both bars is a more credible basis for a label expansion than response data alone.

A combination trial also creates a commercial dependency. Imdelltra plus Imfinzi is a two-company regimen, and AstraZeneca captures value on its side of the prescription. That is normal in oncology, where doublets and triplets cross corporate lines, but it means the economics of a successful combination are shared rather than exclusive to Amgen.

Why the shares did not move on the news

Three explanations are consistent with a stock trading down 0.64% into a broadly lower session. First, expectations: late-stage oncology programmes that reach a readout are often partly priced in, particularly where the mechanism has already been validated by an approved product. Second, magnitude: Amgen is a large-capitalisation biopharmaceutical company with a wide portfolio, and a single product's growth rate — however striking in percentage terms — has to be large in absolute dollars to shift the consolidated picture. Third, macro: with the S&P 500 proxy, the Nasdaq 100 proxy and the Dow proxy all in the red at the same time, sector-specific news was competing with an index-level move.

The intraday pattern reinforces the point. Amgen's high of 395.55 sat above the prior close, and its low of 389.28 sat below it, meaning the stock spent the session on both sides of flat rather than gapping in one direction on the data. That is the trading footprint of a positive-but-expected development, not a re-rating event.

What determines whether this becomes a franchise

Several things need to happen for the combination result to convert into revenue. Regulators must accept the data package and grant a label that reaches the earlier-line population. Payers must agree to reimburse a two-antibody regimen. Clinicians must be persuaded that the tolerability profile supports use in patients who are less heavily pre-treated and therefore have more to lose from toxicity. Each of those is a separate gate, and each takes quarters rather than weeks.

For competitive positioning, the practical test is whether Imdelltra becomes the default partner for checkpoint inhibition in small-cell lung cancer or one of several options. Rival programmes targeting the same disease are in development across the industry, and small-cell has become an unusually active area after decades of stagnation. First-mover advantage in a difficult tumour type is real but not permanent.

The watch list from here

• Dollar disclosure. The next reported quarter should attach an absolute sales figure to the 115% growth rate, which is what allows the franchise to be sized properly.
• Regulatory timing. Any filing or review milestone for the Imdelltra-Imfinzi combination sets the calendar for when earlier-line revenue could begin.
• Data granularity. Full presentation of the 563-patient study — magnitude of the survival benefit, duration of response, discontinuation rates — will determine how enthusiastically oncologists adopt it.
• Growth durability. Whether triple-digit percentage growth persists or decelerates as the treated population expands.

For now the investment case rests on a product accelerating quickly from an undisclosed base, and a combination result that opens a door without yet walking through it. The share price, on a lower day for all three major US benchmarks, says the market is waiting for the numbers behind the percentages.

Key facts

• Imdelltra sales growth: Up 115%
• Phase 3 trial size: 563 patients, Imdelltra plus Imfinzi
• AMGN price: 390.64, -0.64%, as of 18:51 GMT 9 Sep 2026
• Trial outcome: Improved survival and response measures; major goals met

Frequently asked questions

What did the Imdelltra-Imfinzi trial show?

The late-stage study enrolled 563 patients with lung cancer and met its major goals. Amgen reported that the combination of Imdelltra and AstraZeneca's Imfinzi improved both survival and response measures. Response measures track tumour shrinkage, while survival measures track how long patients live — clearing both is a stronger basis for a label expansion than response data alone.

How fast is Imdelltra growing?

Amgen reported that Imdelltra sales surged 115%. The company has not attached an absolute dollar figure to that growth rate in the information available, so the percentage indicates the speed of the launch rather than the scale of the franchise. Growth of that magnitude typically reflects a product still expanding its prescriber base.

How did Amgen shares react?

Amgen traded at 390.64 as of 18:51 GMT on 9 September 2026, down 0.64% from a prior close of 393.17, within a day range of 389.28 to 395.55. The move tracked a generally lower market: the S&P 500, Nasdaq 100 and Dow ETF proxies were all in the red on the session.

Why does combining the two drugs matter commercially?

Imdelltra's current use is largely in patients whose small-cell lung cancer has progressed after prior therapy. Pairing it with a checkpoint inhibitor such as Imfinzi is an attempt to move it earlier in the treatment sequence, where more patients are treated and treatment lasts longer — the main route to turning a specialty launch into a large franchise.

What is small-cell lung cancer and why is it hard to treat?

Small-cell lung cancer is an aggressive lung tumour subtype that often responds initially to platinum-based chemotherapy but relapses quickly, leaving few durable options. It has seen decades of limited therapeutic progress, which is why new mechanisms and combination regimens that demonstrate a survival benefit draw outsized clinical and investor attention.

What should investors watch next?

Four things: an absolute dollar sales figure for Imdelltra in the next reported quarter; regulatory filing and review timing for the combination; full presentation of the 563-patient dataset including the size of the survival benefit and tolerability; and whether triple-digit percentage sales growth persists as the treated population widens.

Sources

• Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals — GuruFocus

Photo: Tima Miroshnichenko · Pexels Licence — source